Kimberly Pechman
Last active: 3/6/2020

Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume.

Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM
Magn Reson Med. 2012 68 (4): 1266-72

PMID: 22213469 · PMCID: PMC3323703 · DOI:10.1002/mrm.23315

Frequently, bevacizumab is combined with chemotherapeutics such as irinotecan, motivated by studies showing improved clinical outcomes compared with historical controls. However, no systematic studies have been performed to determine if and how these drugs should be combined for optimal therapeutic response. The purpose of this study was to characterize the temporal combinations of bevacizumab and irinotecan by measuring the contrast-agent enhanced tumor volumes and relative cerebral blood volume using dynamic susceptibility contrast imaging. The studies, performed in the U87 brain tumor model, show a vascular normalization window with bevacizumab monotherapy and are consistent with clinical indications of no additional benefit in the addition of irinotecan to bevacizumab therapy.

Copyright © 2011 Wiley Periodicals, Inc.

MeSH Terms (18)

Animals Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bevacizumab Blood Volume Blood Volume Determination Brain Neoplasms Camptothecin Cell Line, Tumor Cerebrovascular Circulation Irinotecan Magnetic Resonance Imaging Male Rats Rats, Nude Reproducibility of Results Sensitivity and Specificity Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: